Skip to main content
SpringerLink
Log in

Payloads of Antibody-Drug Conjugates

  • Chapter
  • First Online:
Antibody-Drug Conjugates

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 17))

Abstract

The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs. The structures, mechanisms of action, pharmacokinetics, and toxicities of these toxins are reviewed and discussed. The payloads along with the clinically tested ADCs and their therapeutic areas are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Kelland LR (1996) Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother Pharmacol 38(3):225–232

    Article  CAS  PubMed  Google Scholar 

  • Anderl J, Faulstich H, Hechler T, Kulke M (2013) Antibody–drug conjugate payloads. Methods Mol Biol 1045:51–70

    Article  PubMed  Google Scholar 

  • Bai R, Petit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39(12):1941–1949

    Article  CAS  PubMed  Google Scholar 

  • Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Luduena RF, Hamel E (1993) Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin: correlation with cytotoxicity. Biochem Pharmacol 45(7):1503–1515

    Article  CAS  PubMed  Google Scholar 

  • Beckwith M, Urba WJ, Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Nat Cancer Inst 85(6):483–488

    Article  CAS  PubMed  Google Scholar 

  • Cassady JM, Chan KK, Floss HG, Leistner E (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52(1):1–26

    Article  CAS  PubMed  Google Scholar 

  • Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98–107

    Article  CAS  PubMed  Google Scholar 

  • Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52(1):127–131

    CAS  PubMed  Google Scholar 

  • Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol 21(7):778–784

    Article  CAS  Google Scholar 

  • Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17(1):114–124

    Article  CAS  PubMed  Google Scholar 

  • Drak J, Iwasawa N, Danishefsky S, Crothers DM (1991) The carbohydrate domain of calicheamicin Îł1 I determines its sequence specificity for DNA cleavage. Proc Natl Acad Sci U S A 88(17):7464–7468

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Robert JL, Goldmacher VS, Blättler WA (2006) Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426–4433

    Article  CAS  PubMed  Google Scholar 

  • Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458–1465

    Article  CAS  PubMed  Google Scholar 

  • Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53(14):3336–3342

    CAS  PubMed  Google Scholar 

  • Hoffman MA, Blessing JA, Lentz SS (2003) A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 89(1):95–98

    Article  CAS  PubMed  Google Scholar 

  • Huang AB, Lin CM, Hamel E (1985) Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. Biochem Biophys Res Commun 128(3):1239–1246

    Article  CAS  PubMed  Google Scholar 

  • Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ (1995) Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci U S A 92(23):10506–10510

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Issell BF, Crooke ST (1978) Maytansine. Cancer Treat Rev 5(4):199–207

    Article  CAS  PubMed  Google Scholar 

  • Jacobsen SE, Ruscetti FW, Longo DL, Keller JR (1991) Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells. J Nat Cancer Inst 83(22):1672–1677

    Article  CAS  PubMed  Google Scholar 

  • Kalemkerian GP, Ou X, Adil MR, Rosati R, Khoulani MM, Madan SK, Pettit GR (1999) Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43(6):507–515

    Article  CAS  PubMed  Google Scholar 

  • Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res 17(20):6428–6436

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Vokes EE (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23(5):489–493

    Article  CAS  PubMed  Google Scholar 

  • Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30(26):3234–3241

    Article  CAS  PubMed  Google Scholar 

  • Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, Karim A, Gilmore CJ, Haltiwanger RC, Bryan RF (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94(4):1354–1356

    Article  CAS  PubMed  Google Scholar 

  • Kupchan SM, Komoda Y, Branfman AR, Dailey Jr RG, Zimmerly VA (1974) Novel maytansinoids: structural interrelations and requirements for antileukemic activity. J Am Chem Soc 96(11):3706–3708

    Article  CAS  Google Scholar 

  • Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, McIvor WE, Wang RW, Schnaitman TC (1978) Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem 21(1):31–37

    Article  CAS  PubMed  Google Scholar 

  • Lee MD, Dunne TS, Chang CC, Ellestad GA, Siegel MM, Morton GO, McGahren WJ, Borders DB (1987a) Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calichemicin Îł1 I. J Am Chem Soc 109(11):3466–3468

    Article  CAS  Google Scholar 

  • Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB (1987b) Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin Îł1 I. J Am Chem Soc 109(11):3464–3466

    Article  CAS  Google Scholar 

  • Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA (2010) Maytansine and cellular metabolites of antibody–maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9(10):2689–2699

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Luesch H, Harrigan GG, Goetz G, Horgen FD (2002) The cyanobacterial origin of potent anticancer agents originally isolated from sea hares. Curr Med Chem 9(20):1791–1806

    Article  CAS  PubMed  Google Scholar 

  • Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Abbruzzese JL (2000) Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6(4):1293–1301

    CAS  PubMed  Google Scholar 

  • Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG (1976) Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72(1):47–54

    Article  CAS  PubMed  Google Scholar 

  • Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA (1999) Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 44(5):395–402

    Article  CAS  PubMed  Google Scholar 

  • Newman RA, Fuentes A, Covey JM, Benvenuto JA (1994) Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab Dispos 22(3):428–432

    CAS  PubMed  Google Scholar 

  • Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109(22):6883–6885

    Article  CAS  Google Scholar 

  • Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Ames MM (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5(3):525–531

    CAS  PubMed  Google Scholar 

  • Remillard S, Rebhun LI, Howie GA, Kupchan SM (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189(4207):1002–1005

    Article  CAS  PubMed  Google Scholar 

  • Thorson JS, Sievers EL, Ahlert J, Shepard E, Whitwam RE, Onwueme KC, Ruppen M (2000) Understanding and exploiting nature’s chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 6(18):1841–1879

    Article  CAS  PubMed  Google Scholar 

  • Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21(2):211–222

    Article  CAS  PubMed  Google Scholar 

  • Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M (2000) Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6(11):4205–4208

    CAS  PubMed  Google Scholar 

  • Von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, Rogatko A (2004) Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma 8(4):107–111

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wolpert-Defilippes MK, Adamson RH, Cysyk RL, Johns DG (1975) Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide. Biochem Pharmacol 24(6):751–754

    Article  CAS  PubMed  Google Scholar 

  • Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA, Chari RV (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49(14):4392–4408

    Article  CAS  PubMed  Google Scholar 

  • Wolpert-DeFilippes MK, Bono Jr VH, Dion RL, Johns DG (1975) Initial studies on maytansine-induced metaphase arrest in 11210 mĂĽrine leukemia cells. Biochem Pharmacol 24(18):1735–1738

    Article  CAS  PubMed  Google Scholar 

  • Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calicheamicin Îł1 I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240(4856):1198–1201

    Article  CAS  PubMed  Google Scholar 

  • Zein N, Poncin M, Nilakantan R, Ellestad GA (1989) Calicheamicin Îł1 I and DNA: molecular recognition process responsible for site-specificity. Science 244(4905):697–699

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA, USA

    Chalet Tan

Authors
  1. Chalet Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chalet Tan .

Editor information

Editors and Affiliations

  1. Western University of Health Sciences, Department of Pharmaceutical Sciences, Pomona, California, USA

    Jeffrey Wang

  2. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Wei-Chiang Shen

  3. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Jennica L. Zaro

Rights and permissions

Reprints and permissions

Copyright information

© 2015 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Tan, C. (2015). Payloads of Antibody-Drug Conjugates. In: Wang, J., Shen, WC., Zaro, J. (eds) Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-319-13081-1_2

Download citation

Publish with us

Policies and ethics

Search

Navigation